{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:25:12Z","timestamp":1779942312051,"version":"3.53.1"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"16","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,8,15]]},"DOI":"10.2146\/ajhp110687","type":"journal-article","created":{"date-parts":[[2012,8,1]],"date-time":"2012-08-01T21:54:41Z","timestamp":1343858081000},"page":"1389-1393","source":"Crossref","is-referenced-by-count":13,"title":["A new epoprostenol formulation for the treatment of pulmonary arterial hypertension"],"prefix":"10.1093","volume":"69","author":[{"given":"Amaris","family":"Fuentes","sequence":"first","affiliation":[{"name":"The Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aida","family":"Coralic","sequence":"additional","affiliation":[{"name":"The Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle L.","family":"Dawson","sequence":"additional","affiliation":[{"name":"The Methodist Hospital, Houston, TX"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041607095064800_b1-0691389","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association","volume":"53","author":"McLaughlin","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"2019041607095064800_b2-0691389","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.rmed.2010.12.018","article-title":"Treatment of pulmonary arterial hypertension: the role of prostacyclin and prostaglandin analogs","volume":"105","author":"Safdar","year":"2011","journal-title":"Respir Med."},{"key":"2019041607095064800_b3-0691389","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMra040291","article-title":"Treatment of pulmonary arterial hypertension","volume":"351","author":"Humbert","year":"2004","journal-title":"N Engl J Med."},{"key":"2019041607095064800_b4-0691389","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1016\/j.jacc.2009.04.017","article-title":"Updated evidence-based treatment algorithm in pulmonary arterial hypertension","volume":"54","author":"Barst","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"2019041607095064800_b5-0691389","volume-title":"Flolan (epoprostenol) prescribing information","year":"2011"},{"key":"2019041607095064800_b6-0691389","volume-title":"Epoprostenol prescribing information","year":"2008"},{"key":"2019041607095064800_b7-0691389","doi-asserted-by":"crossref","first-page":"485","DOI":"10.7326\/0003-4819-112-7-485","article-title":"Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol)","volume":"112","author":"Rubin","year":"1990","journal-title":"Ann Intern Med."},{"key":"2019041607095064800_b8-0691389","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJM199602013340504","article-title":"A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension","volume":"334","author":"Barst","year":"1996","journal-title":"N Engl J Med."},{"key":"2019041607095064800_b9-0691389","doi-asserted-by":"crossref","first-page":"425","DOI":"10.7326\/0003-4819-132-6-200003210-00002","article-title":"Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease","volume":"132","author":"Badesch","year":"2000","journal-title":"Ann Intern Med."},{"key":"2019041607095064800_b10-0691389","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1161\/01.CIR.99.14.1858","article-title":"Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects","volume":"99","author":"Rosenzweig","year":"1999","journal-title":"Circulation."},{"key":"2019041607095064800_b11-0691389","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1161\/01.CIR.0000029100.82385.58","article-title":"Survival in primary pulmonary hypertension: the impact of epoprostenol","volume":"106","author":"McLaughlin","year":"2002","journal-title":"Circulation."},{"key":"2019041607095064800_b12-0691389","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0735-1097(02)02012-0","article-title":"Long-term intravenous epoprostenol infusion in primary pulmonary hypertension","volume":"40","author":"Sitbon","year":"2002","journal-title":"J Am Coll Cardiol."},{"key":"2019041607095064800_b13-0691389","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982\u20132006","volume":"30","author":"Thenappan","year":"2007","journal-title":"Eur Resp J."},{"key":"2019041607095064800_b14-0691389","volume-title":"Veletri (epoprostenol) prescribing information","year":"2011"},{"key":"2019041607095064800_b15-0691389","volume-title":"NDA 22\u2013260, epoprostenol for injection, 1.5 mg vial","author":"Center for Drug Evaluation and Research, Food and Drug Administration","year":"2008"},{"key":"2019041607095064800_b16-0691389","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1097\/00000542-200404000-00040","article-title":"Rebound pulmonary hypertension and cardiogenic shock after withdrawal of inhaled prostacyclin","volume":"100","author":"Augoustides","year":"2004","journal-title":"Anesthesiology."},{"key":"2019041607095064800_b17-0691389","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1097\/00000542-200412000-00040","article-title":"Treatment of rebound pulmonary hypertension: why not sil-denafil?","volume":"101","author":"Augoustides","year":"2004","journal-title":"Anesthesiology."},{"key":"2019041607095064800_b18-0691389","unstructured":"The ASHP discussion guide on USP chapter 797 for compounding sterile preparations. www.ashp.org\/s_ashp\/docs\/files\/discguide797-2008.pdf (accessed 2012 May 16)."},{"key":"2019041607095064800_b19-0691389","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1592\/phco.2006.26.1.68","article-title":"Pharmacotherapy for idiopathic pulmonary arterial hypertension during the past 25 years","volume":"26","author":"Hackman","year":"2006","journal-title":"Pharmacotherapy."},{"key":"2019041607095064800_b20-0691389","volume-title":"Remodulin (treprostinil) prescribing information","year":"2012"},{"key":"2019041607095064800_b21-0691389","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1164\/ajrccm.165.6.2106079","article-title":"Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial","volume":"165","author":"Simonneau","year":"2002","journal-title":"Am J Respir Crit Care Med."},{"key":"2019041607095064800_b22-0691389","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1097\/00005344-200302000-00019","article-title":"Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension","volume":"41","author":"McLaughlin","year":"2003","journal-title":"J Cardiovasc Pharmacol."},{"key":"2019041607095064800_b23-0691389","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1378\/chest.121.5.1561","article-title":"Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension","volume":"121","author":"Vachi\u00e9ry","year":"2002","journal-title":"Chest."},{"key":"2019041607095064800_b24-0691389","volume-title":"Red Book Online 2012 [online monograph]"},{"key":"2019041607095064800_b25-0691389","unstructured":"Actelion Pharmaceuticals Ltd. Marketed products, September2011. www.actelion.com\/documents\/corporate\/fact_sheet\/FS_MarketedProducts.pdf (accessed 2012 May 16)."},{"key":"2019041607095064800_b26-0691389","unstructured":"Institute for Safe Medication Practices. ISMP\u2019s list of high-alert medications. www.ismp.org\/Tools\/highalertmedications.pdf (accessed 2012 Apr 30)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/69\/16\/1389\/28455225\/ajhp1389.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,16]],"date-time":"2019-04-16T11:19:26Z","timestamp":1555413566000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/69\/16\/1389\/5111954"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,8,15]]},"references-count":26,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2012,8,15]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp110687","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,8,15]]},"published":{"date-parts":[[2012,8,15]]}}}